Clinical Trial Update: Levetiracetam Treatment of L-dopa Induced Dyskinesias [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating levetiracetam for L-dopa-induced dyskinesias in Parkinson disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesias
• Parkinson Disease

Drugs mentioned

• LEVETIRACETAM (levetiracetam)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Dyskinesias, Parkinson Disease | Phase 2 | Status: COMPLETED